<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Zealand Pharma — Maj 2024]]></title><description><![CDATA[<p dir="auto">OVERBLIK: Disse selskaber er shortet på det danske aktiemarked <a href="https://www.proinvestor.com/investornyt/1152886/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked" rel="nofollow ugc">https://www.proinvestor.com/investornyt/1152886/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400831/zealand-pharma-maj-2024</link><generator>RSS for Node</generator><lastBuildDate>Sat, 06 Jun 2026 09:04:01 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400831.rss" rel="self" type="application/rss+xml"/><pubDate>Wed, 01 May 2024 03:04:52 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 13:15:50 GMT]]></title><description><![CDATA[<p dir="auto">Zealand Pharma: Ekspertpanel anbefaler nødpen udlicenseret til Novo godkendt i EU <a href="https://proinvestor.com/investornyt/1167142/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu" rel="nofollow ugc">https://proinvestor.com/investornyt/1167142/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035515</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035515</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 31 May 2024 13:15:50 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 12:23:23 GMT]]></title><description><![CDATA[<p dir="auto">The positive opinion from the CHMP will be referred to the European Commission (EC) for a final decision whether to grant marketing authorization in the European Union (EU). Zealand expects this decision within approximately three months. Dasiglucagon injection was approved by the U.S. FDA in March 2021 under the brand name Zegalogue<img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/00ae.png?v=ace6278a214" class="not-responsive emoji emoji-android emoji--registered" style="height:23px;width:auto;vertical-align:middle" title="®" alt="®" />.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035516</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035516</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 31 May 2024 12:23:23 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 12:22:39 GMT]]></title><description><![CDATA[<p dir="auto">"We are very pleased that the European regulatory authorities have recommended approval of dasiglucagon as a rescue treatment for very low blood sugar in people with diabetes," said Adam Steensberg, Chief Executive Officer of Zealand Pharma. "This is an important step in achieving our ambition of bringing this product to many more patients around the world through our partnership with Novo Nordisk, a global leader in diabetes."</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035517</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035517</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 31 May 2024 12:22:39 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 12:22:22 GMT]]></title><description><![CDATA[<p dir="auto">Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending granting marketing authorization for dasiglucagon solution for injection in the treatment of severe hypoglycemia in adults, adolescents, and chil</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035514</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035514</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 31 May 2024 12:22:22 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 12:21:59 GMT]]></title><description><![CDATA[<p dir="auto">Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035518</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035518</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Fri, 31 May 2024 12:21:59 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 09:30:16 GMT]]></title><description><![CDATA[<p dir="auto">Goldman Sachs ser det globale fedmemarked vokse til 130 mia. dollar i 2030 <a href="https://proinvestor.com/investornyt/1166978/goldman-sachs-ser-det-globale-fedmemarked-vokse-til-130-mia-dollar-i-2030" rel="nofollow ugc">https://proinvestor.com/investornyt/1166978/goldman-sachs-ser-det-globale-fedmemarked-vokse-til-130-mia-dollar-i-2030</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035512</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035512</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Fri, 31 May 2024 09:30:16 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 09:24:40 GMT]]></title><description><![CDATA[<p dir="auto">Zealand Pharma: Ekspertpanel anbefaler nødpen udlicenseret til Novo godkendt i EU <a href="https://proinvestor.com/investornyt/1166987/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu" rel="nofollow ugc">https://proinvestor.com/investornyt/1166987/zealand-pharma-ekspertpanel-anbefaler-nodpen-udlicenseret-til-novo-godkendt-i-eu</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035511</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035511</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Fri, 31 May 2024 09:24:40 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 06:07:04 GMT]]></title><description><![CDATA[<p dir="auto">Jefferies Global Healthcare Conference, June 4-6 in New York City…….. Goldman Sachs 45th Annual Global Healthcare Conference, June 10-13 in Miami</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035507</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035507</guid><dc:creator><![CDATA[Aps_invest]]></dc:creator><pubDate>Fri, 31 May 2024 06:07:04 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Fri, 31 May 2024 06:06:07 GMT]]></title><description><![CDATA[<p dir="auto">Spændende om det kan øge interessen i USA:<br />
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035513</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035513</guid><dc:creator><![CDATA[Aps_invest]]></dc:creator><pubDate>Fri, 31 May 2024 06:06:07 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Thu, 30 May 2024 10:43:25 GMT]]></title><description><![CDATA[<p dir="auto">Kort video....<br />
Pharma- og biotekopdatering uge 22 | Genmab, Zealand Pharma og Novo Nordisk <a href="https://proinvestor.com/boards/120686" rel="nofollow ugc">https://proinvestor.com/boards/120686</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035506</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035506</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Thu, 30 May 2024 10:43:25 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Thu, 30 May 2024 03:00:11 GMT]]></title><description><![CDATA[<p dir="auto">OVERBLIK: Disse selskaber er shortet på det danske aktiemarked <a href="https://proinvestor.com/investornyt/1166285/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked" rel="nofollow ugc">https://proinvestor.com/investornyt/1166285/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035504</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035504</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Thu, 30 May 2024 03:00:11 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Wed, 29 May 2024 13:54:48 GMT]]></title><description><![CDATA[<p dir="auto">Video: Den Europæiske Centralbank ECB sætter formentlig renten ned i næste uge, men hvor meget? Hør også om NVIDIA, Mærsk og DSV's interesse for at købe DB Schenker, samt om de to danske biotekselskaber Zealand Pharma, Novo Nordisk og Genmab. <a href="https://proinvestor.com/boards/120672" rel="nofollow ugc">https://proinvestor.com/boards/120672</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035508</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035508</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 29 May 2024 13:54:48 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Wed, 29 May 2024 10:07:54 GMT]]></title><description><![CDATA[<p dir="auto">Polar Capital har således øget antallet af af aktier med 3%.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035509</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035509</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 29 May 2024 10:07:54 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Wed, 29 May 2024 10:06:30 GMT]]></title><description><![CDATA[<p dir="auto"><a href="https://ml-eu.globenewswire.com/Resource/Download/65d79694-38bf-4a77-8f4c-5505f6138a69" rel="nofollow ugc">https://ml-eu.globenewswire.com/Resource/Download/65d79694-38bf-4a77-8f4c-5505f6138a69</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035503</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035503</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 29 May 2024 10:06:30 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Wed, 29 May 2024 10:05:53 GMT]]></title><description><![CDATA[<p dir="auto">Meddelelse: As of 22 May 2024, Polar Capital holds nominally 3,138,798 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 5.01% of the total share capital and total voting rights in Zealand Pharma A/S.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035500</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035500</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 29 May 2024 10:05:53 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Wed, 29 May 2024 03:08:10 GMT]]></title><description><![CDATA[<p dir="auto">OVERBLIK: Disse selskaber er shortet på det danske aktiemarked <a href="https://proinvestor.com/investornyt/1165660/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked" rel="nofollow ugc">https://proinvestor.com/investornyt/1165660/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035505</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035505</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 29 May 2024 03:08:10 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Tue, 28 May 2024 06:52:53 GMT]]></title><description><![CDATA[<p dir="auto">Man vil ganske givet også se andre fedme stoffer blive testet som kombi til de patienter der for alvor har høj BMI, og hvor de eksisterende slet ikke kan give stort nok vægttab</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035501</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035501</guid><dc:creator><![CDATA[troldmanden]]></dc:creator><pubDate>Tue, 28 May 2024 06:52:53 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Tue, 28 May 2024 06:51:55 GMT]]></title><description><![CDATA[<p dir="auto">Generelt vil vi se amylin stoffer blive kombineret. Og så også stoffer der har positiv impact på muskelmasse</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035499</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035499</guid><dc:creator><![CDATA[troldmanden]]></dc:creator><pubDate>Tue, 28 May 2024 06:51:55 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Tue, 28 May 2024 06:51:18 GMT]]></title><description><![CDATA[<p dir="auto">Mht prisen ved at kombinere flere stoffer. Vi kommer til at se rigtig mange kombi behandlinger. Novo står jo kun ca 18 mdr fra mulig godkendelse af CagriSema som jo er en kombi. Og ja så bliver produktions cost lidt højere. Men det har ingen betyden i denne henseende da bruttomargin allerede er høj</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035510</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035510</guid><dc:creator><![CDATA[troldmanden]]></dc:creator><pubDate>Tue, 28 May 2024 06:51:18 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Tue, 28 May 2024 06:49:15 GMT]]></title><description><![CDATA[<p dir="auto">DevOp ja sådan er det jo med alt i denne branche. At "man lige skal igennem kliniske forsøg" <img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/1f642.png?v=ace6278a214" class="not-responsive emoji emoji-android emoji--slightly_smiling_face" style="height:23px;width:auto;vertical-align:middle" title=":-)" alt="🙂" /> Jeg ser det som meget sandsynligt der er en betydende positiv impact på muskelvæv. Men præcis hvor meget, og ikke mindst safety profilen, det er det store spørgsmål. AZ smider heller ikke 550 mio kr for et præklinisk stof uden at føle sig meget sikker på den indledende impact</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035497</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035497</guid><dc:creator><![CDATA[troldmanden]]></dc:creator><pubDate>Tue, 28 May 2024 06:49:15 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Tue, 28 May 2024 03:15:29 GMT]]></title><description><![CDATA[<p dir="auto">OVERBLIK: Disse selskaber er shortet på det danske aktiemarked <a href="https://proinvestor.com/investornyt/1165135/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked" rel="nofollow ugc">https://proinvestor.com/investornyt/1165135/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035498</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035498</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 28 May 2024 03:15:29 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Mon, 27 May 2024 08:17:45 GMT]]></title><description><![CDATA[<p dir="auto">603 så vi igen pre-fredag kursmæssigt</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035496</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035496</guid><dc:creator><![CDATA[Svingtraderen]]></dc:creator><pubDate>Mon, 27 May 2024 08:17:45 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Mon, 27 May 2024 05:40:59 GMT]]></title><description><![CDATA[<p dir="auto">Trold, nu skal de vel lige igennem en fase 2 med en kombi, før vi kan sige, at der ikke længere er noget tab af muskelmasse sammen med GLP-1. Det gør under alle omstændigheder behandlingen dyrere med 2 medikamenter - hvilket indrømmet evt også kan være bedre sammen med Amylin. Men jeg ser stadig forskellen i bivirkningsprofil som det potentielt største win for Amylin, specielt når vi kigger på drop out og længden af behandling med GLP-1.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035502</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035502</guid><dc:creator><![CDATA[DevOp]]></dc:creator><pubDate>Mon, 27 May 2024 05:40:59 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand Pharma — Maj 2024 on Mon, 27 May 2024 05:17:37 GMT]]></title><description><![CDATA[<p dir="auto">Ups forkert chat <img src="https://dev.proinvestor.com/forum/assets/plugins/nodebb-plugin-emoji/emoji/android/1f642.png?v=ace6278a214" class="not-responsive emoji emoji-android emoji--slightly_smiling_face" style="height:23px;width:auto;vertical-align:middle" title=":-)" alt="🙂" /></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8035492</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8035492</guid><dc:creator><![CDATA[troldmanden]]></dc:creator><pubDate>Mon, 27 May 2024 05:17:37 GMT</pubDate></item></channel></rss>